The 2022 Agenda Has Been Released!

Meet the experts from Euromonitor, Real Isolates, Eurofins Food Chemistry Testing, and many more!

Content in (EST) Eastern Standard Time

Session I: The CBD & Hemp Industry: Today & the Future
Beyond Hype & Hope: Global Cannabis Blooms
As the global cannabis industry emerges into a new era of pragmatic optimism, conscious of false dawns and corporate underperformance but encouraged by increasing normalisation and the international spread of legalisation, this session will assess the current state and future prospects for the world CBD and cannabis market.
Leveraging proprietary data and proven thought leadership to surface the key consumer and industry trends and international size of opportunity the session will be indispensable in plotting a path for an industry moving from niche taboo into the mainstream.
Shane MacGuill, Global Lead, Nicotine & Cannabis, Euromonitor
Spiros Malandrakis, Head of Alcoholic Drinks Research, Euromonitor
Shane MacGuill | Global Lead - Nicotine & Cannabis, Euromonitor
Panel: Opportunities and Growth as the Industry Moves Forward
The CBD sector continues to develop and innovate so that it can exploit new opportunities in line with technological and societal changes. This panel looks to explore the views and thoughts of participants for opportunities (and threats) for the industry.

  • Matt Zehner, Senior Insights Analyst, Brightfield Group
  • Cynthia Cabrera, CEO, Cating Group
  • Karla Rodriguez, Lab Director for Enthalpy’s Cannabis Smoke and Vapor (CSV) testing lab, Enthalpy
More panelists to come!
Networking Break
Session II: What You Need to Know About the Current Regulatory Landscape
Fireside Chat: Changing Tides within the Industry
CBD & Changing Global Regulatory Landscape
Session III: Working Within the Marketplace
Hemp & CBD: Adapting to Industry (Panel discussion to follow)
Discussion of how third party labs are responding to industry expansion and regulatory requirements by developing new methods with lower limits and validations to meet compliance and product innovation. Discussion of the importance of selecting and partnering with a reputable third party laboratory and the need for further industry collaboration and standardization.
When the presentation ends, a panel discussion will expand upon the topic points Vanessa examined.
Moderator: Vanessa Snyder, Business Development Director – Hemp and Botanicals, Eurofins Food Chemistry Testing
  • Chelsea Pipkin, Vice President of Quality Assurance, Open Book Extracts
  • Sibyl Swift, Ph.D., Vice President, Scientific & Regulatory Affairs, cbdMD, Inc.
  • Stephanie Fitzgerald, Analytical Chemist, Charlotte’s Web
Lunch Break
Labeling and Marketing Hemp-CBD Products: Best Practices & Pitfalls to Avoid
Asa Waldstein reviews best practices, and common mistakes companies make when marketing and labeling hemp-CBD products.
  • Anatomy of a CBD supplement label. A detailed review of how to comply with state and federal regulations.
  • Marketing insights: A review of recent regulatory trends, common marketing oversights, and best practices for compliance. This includes looking at the nuances of social media engagement, reposting, and infographics. Asa will also discuss other enforcement areas, such as influencer marketing and blogs.

Asa Waldstein | AHPA Cannabis Committee Chair, Principal Supplement Advisory Group
Supply Chain Issues & Important Packaging Updates
Abstract TBD
Julie Saltzman, Director of Cannabis Business Development, Berlin Packaging
Session V: Envisioning the Future
Beyond the Basic Cannabinoids – Exploring the Chemodiversity of Hemp Cannabis for Unique Therapeutic Profiles
Humanity has been using Cannabis sativa for medicinal purposes for thousands of years. The two major subtypes have been separated traditionally by their purpose: hemp Cannabis has been used for food and fiber while medicinal Cannabis was cultivated for its active secondary metabolites that lead to therapeutic effects. The recent legal liberation of cannabidiol (CBD) has created an opportunity for the renewed exploration of medicinal benefits of hemp Cannabis containing less than 0.3% D9-tetrahydrocannabinol (D9-THC). Though CBD has been the focus of the industry thus far, hemp Cannabis contains hundreds of unique molecules that can be combined into millions of unique formulations. Novel Cannabis sativa strains high in cannabigerol (CBG) are emerging as well as the production of isolated rare cannabinoids from hemp such as cannabinol (CBN), cannabichromene (CBC), cannabicitran (CBCT), and cannabidivarin (CBDV). Qualitative data collected from the community indicate that these rare cannabinoids have unique effects in addition to altering the effects of the primary cannabinoids CBD and D9-THC. In addition, Cannabis flower contains terpenes, flavonoids, and other bioactive molecules that are present in full spectrum products. This vast chemodiversity is often further expanded by heat transformation when Cannabis flower is smoked or vaporized – the most popular method of consumption. These complex formulations likely have unique molecular mechanisms that correlate directly to unique therapeutic effects; and they are currently being used by the community! Understanding Cannabis in the context of chemodiversity will lead to innovative products, reproducibility, scientific and medical validity, and the overall growth of our community.

Dr. Miyabe Shields | Chief Science Officer, Real Isolates
Industrial Hemp – Seed and Stalk
Seed and stalk material is generally what people refer to when they specifically say “Industrial Hemp”. In a brief review we are going to review the differences in this type of production compared to floral hemp and then outline where I see future opportunities for the industry. This could include opportunities of overlap between cannabinoid and industrial hemp products.

Morgan Tweet | Chief Operating Officer, IND HEMP and Executive Director,The Hemp Feed Coalition
Closing Remarks